(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Follistatin increases the expression of ______, which is critical for nitric oxide production.
"In our experiments, the reduction in oxidative stress was measured as a decrease in the fold change of ______.
FST was administered every ______ day.
Which hypertensive animal model did we use?
___________
The fluorescent product produced in the AmplexRed assay is called ______.
What is the endogenous protein we studied that antagonizes activin?
_____________
Enhanced NO bioavailability indicates improved ______.
Follistatin treatment reduced blood pressure by approximately ______ mmHg.
FST’s antioxidant effect is lost if it is ______.
What assay did we use to quantify hydrogen peroxide?
_____________
Hypertension is defined by sustained blood pressure above ____ mmHg.
What does the abbreviation 'SHR' stand for?
_____________
Which type of assay is used to evaluate NO levels in our study: fluorometric or colorimetric?
_____________
Follistatin treatment induces ______ of PVAT, a phenotype associated with improved vascular function.
Follistatin is known to neutralize signaling by ______.
Which protein marker indicates a brown adipose phenotype in PVAT?
_____________
Which normotensive strain served as our control?
_____________
FST lowers ROS levels, as indicated by a decrease in ______ levels.
In our study, follistatin was administered to SHRs over a period of ______ weeks.
Our study shows that blocking activin signaling reduces ______ production.
Neutralizing antibodies targeted activin A and ______.
Follistatin retains its antioxidant effect even when denatured.
True/False
Follistatin must maintain its proper ______ to be functional.
